GNPX.US Genprex Inc

Healthcare Biotechnology USA Stocks
2.08 USD
Close of Nov 13, 2026
1.71 98.76
Market cap
USD 1.70M
P/E
-
P/B
0.12x
ROE
-127.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GNPX.US undervalued?

Graham number

The Graham number of Genprex Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genprex Inc fundamental analysis

No fundamental analysis for Genprex Inc yet.

Genprex Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genprex Inc

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead pro…

Full company profile